What medications are recommended for an adult with stage 2 chronic kidney disease (CKD)?

Medication for Stage 2 CKD

For adults with stage 2 CKD (eGFR 60-89 mL/min/1.73 m²), medication selection depends primarily on albuminuria level and diabetes status, with SGLT2 inhibitors and RAS inhibitors forming the cornerstone of therapy.

Primary Treatment Algorithm

1. SGLT2 Inhibitors - First-Line for Most Patients

Start an SGLT2 inhibitor if the patient has:

• ACR ≥200 mg/g (≥20 mg/mmol) - Strong recommendation regardless of diabetes status 1
• Type 2 diabetes with eGFR ≥20 - Strong recommendation 1
• Heart failure - Strong recommendation irrespective of albuminuria level 1

The 2024 KDIGO guidelines provide the strongest (1A) evidence for SGLT2 inhibitors in these scenarios, representing a major shift in CKD management 1. These agents reduce mortality, cardiovascular events, hospitalization for heart failure, and kidney failure progression 2.

Key implementation points:

• Continue SGLT2i even if eGFR drops below 20 during treatment 1
• Withhold during prolonged fasting, surgery, or critical illness (ketosis risk) 1
• The initial eGFR dip is expected and not a reason to discontinue 1

2. RAS Inhibitors (ACE Inhibitors or ARBs)

Start ACEi or ARB based on albuminuria:

Without diabetes:

• ACR >300 mg/g (A3 - severely increased albuminuria): Strong recommendation (1B) 1
• ACR 30-300 mg/g (A2 - moderately increased albuminuria): Weak recommendation (2C) 1

With diabetes:

• ACR ≥30 mg/g (A2 or A3): Strong recommendation (1B) 1

Critical dosing guidance:

• Use the highest approved tolerated dose - benefits were demonstrated at these doses in trials 1
• Check BP, creatinine, and potassium within 2-4 weeks of initiation 1
• Continue therapy unless creatinine rises >30% within 4 weeks 1
• Do NOT stop when eGFR falls below 30 - continue therapy 1

For patients with normal albuminuria (ACR <30 mg/g):

• Consider RASi for specific indications: hypertension or heart failure with reduced ejection fraction 1

3. Additional Therapies for Specific Populations

Nonsteroidal Mineralocorticoid Receptor Antagonists (e.g., finerenone):

• Reserved for type 2 diabetes patients with:
  • eGFR >25 mL/min/1.73 m²
  • Normal potassium (≤4.8 mmol/L)
  • ACR >30 mg/g despite maximum tolerated RASi 1
• Can be added to RASi + SGLT2i combination 1
• Requires careful potassium monitoring (check at 1 month, then every 4 months) 1

GLP-1 Receptor Agonists:

• For type 2 diabetes patients not at glycemic target despite metformin and SGLT2i 1
• Choose long-acting agents with documented cardiovascular benefits 1

Common Pitfalls to Avoid

1. Don't discontinue RASi when eGFR declines - this is the most common error. Continue unless creatinine rises >30% acutely or eGFR <15 with uremic symptoms 1

2. Don't withhold SGLT2i in stage 2 CKD due to "preserved" kidney function - the benefit is greatest when started early, particularly with albuminuria 2

3. Don't underdose RASi - use maximum tolerated doses, not "renal doses" 1

4. Don't stop SGLT2i for initial eGFR dip - this is hemodynamic and expected 1

5. Manage hyperkalemia aggressively rather than stopping RASi - use dietary modification, diuretics, or potassium binders to maintain therapy 1

Risk Stratification Context

Stage 2 CKD patients fall into different risk categories based on albuminuria 2:

• Low risk: ACR <30 mg/g (consider SGLT2i weakly, RASi for other indications)
• Moderate risk: ACR 30-300 mg/g (suggest SGLT2i and RASi)
• High risk: ACR >300 mg/g (strongly recommend both SGLT2i and RASi)

The evidence base has evolved dramatically, with SGLT2 inhibitors now representing a paradigm shift in CKD management alongside traditional RAS inhibition 3, 4. The 2024 KDIGO guidelines reflect this by elevating SGLT2 inhibitors to first-line status for most patients with significant albuminuria or diabetes 1.